These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 17926203)
21. Bordetella pertussis, Finland and France. Caro V; Elomaa A; Brun D; Mertsola J; He Q; Guiso N Emerg Infect Dis; 2006 Jun; 12(6):987-9. PubMed ID: 16707058 [TBL] [Abstract][Full Text] [Related]
22. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? He Q; Mäkinen J; Berbers G; Mooi FR; Viljanen MK; Arvilommi H; Mertsola J J Infect Dis; 2003 Apr; 187(8):1200-5. PubMed ID: 12695998 [TBL] [Abstract][Full Text] [Related]
23. Identification of linear B epitopes of pertactin of Bordetella pertussis induced by immunization with whole and acellular vaccine. da Silva FR; Napoleão-Pego P; De-Simone SG Vaccine; 2014 Oct; 32(47):6251-8. PubMed ID: 25252193 [TBL] [Abstract][Full Text] [Related]
24. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Hijnen M; de Voer R; Mooi FR; Schepp R; Moret EE; van Gageldonk P; Smits G; Berbers GA Vaccine; 2007 Aug; 25(31):5902-14. PubMed ID: 17597264 [TBL] [Abstract][Full Text] [Related]
26. Determination of pertactin IgG antibodies for the diagnosis of pertussis. Trollfors B; Lagergård T; Gunnarsson E; Taranger J Clin Microbiol Infect; 2003 Jul; 9(7):585-9. PubMed ID: 12925096 [TBL] [Abstract][Full Text] [Related]
27. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777 [TBL] [Abstract][Full Text] [Related]
28. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. Xu Y; Wang Y; Tan Y; Zhang H; Wu L; Wang L; Hou Q; Zhang S BMC Microbiol; 2009 Dec; 9():274. PubMed ID: 20040101 [TBL] [Abstract][Full Text] [Related]
29. Protective role of immunoglobulin G antibodies to filamentous hemagglutinin and pertactin of Bordetella pertussis in Bordetella parapertussis infection. He Q; Edelman K; Arvilommi H; Mertsola J Eur J Clin Microbiol Infect Dis; 1996 Oct; 15(10):793-8. PubMed ID: 8950556 [TBL] [Abstract][Full Text] [Related]
30. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Boursaux-Eude C; Thiberge S; Carletti G; Guiso N Vaccine; 1999 Jun; 17(20-21):2651-60. PubMed ID: 10418915 [TBL] [Abstract][Full Text] [Related]
31. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640 [TBL] [Abstract][Full Text] [Related]
32. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007 [TBL] [Abstract][Full Text] [Related]
33. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013. Quinlan T; Musser KA; Currenti SA; Zansky SM; Halse TA Mol Cell Probes; 2014 Aug; 28(4):138-40. PubMed ID: 24365130 [TBL] [Abstract][Full Text] [Related]
34. Whooping cough surveillance in France in pediatric private practice in 2006-2015. Guiso N; Levy C; Romain O; Guillot S; Werner A; Rondeau MC; Béchet S; Cohen R Vaccine; 2017 Oct; 35(45):6083-6088. PubMed ID: 28974408 [TBL] [Abstract][Full Text] [Related]
35. Pertussis vaccine: a critique. Robbins JB; Schneerson R; Keith JM; Miller MA; Kubler-Kielb J; Trollfors B Pediatr Infect Dis J; 2009 Mar; 28(3):237-41. PubMed ID: 19165133 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice]. Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J Med Dosw Mikrobiol; 2007; 59(2):123-35. PubMed ID: 17929410 [TBL] [Abstract][Full Text] [Related]
37. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908 [TBL] [Abstract][Full Text] [Related]
38. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Bergfors E; Trollfors B; Taranger J; Lagergård T; Sundh V; Zackrisson G Int J Infect Dis; 1999; 3(3):140-6. PubMed ID: 10460925 [TBL] [Abstract][Full Text] [Related]
39. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor. Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630 [TBL] [Abstract][Full Text] [Related]
40. A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis. Alvarez Hayes J; Oviedo JM; Valdez H; Laborde JM; Maschi F; Ayala M; Shah R; Fernandez Lahore M; Rodriguez ME Microbiol Immunol; 2017 Oct; 61(10):407-415. PubMed ID: 28857261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]